John Chadwick

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

Luciano Nicosia, Gary J. Spencer, Nigel Brooks et al. · Cancer Cell · 2023 · 111 citations · Full text

Medicine, Oncology, Pharmacology +17

Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia

Gauri Deb, Bettina Wingelhofer, Fabio M. R. Amaral et al. · Leukemia · 2019 · 37 citations · Full text

Medicine, Oncology, Pharmacology +16

Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3 Confers Differentiation Block in Acute Leukemia

Tim D.D. Somerville, Fabrizio Simeoni, John Chadwick et al. · Cell Reports · 2018 · 32 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association

Roberto Paredes, Marion Schneider, Adam Stevens et al. · Nucleic Acids Research · 2018 · 13 citations · Full text

Medicine, Molecular Biology, Oncology +16

CCS1477, a Novel p300/CBP Bromodomain Inhibitor, Enhances Efficacy of Azacitidine and Venetoclax in Pre-Clinical Models of Acute Myeloid Leukaemia and Lymphoma

Nigel Brooks, Tomasz Knurowski, Andrew Hughes et al. · Blood · 2021 · 12 citations

Medicine, Oncology, Pharmacology +15